PTC THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.7B | $806.8M | $937.8M | $698.8M | $538.6M |
| Selling, general & administrative | $347.1M | $300.9M | $332.5M | $326.0M | $285.8M |
| Research and development | $455.2M | $534.5M | $666.6M | $651.5M | $540.7M |
| Operating expenses | $863.7M | $1.1B | $1.4B | $1.1B | $913.0M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M |
| Pretax income | $696.6M | -$363.1M | -$696.1M | -$587.5M | -$518.3M |
| Income tax expense | $14.0M | $176,000 | -$69.5M | -$28.5M | $5.6M |
| Net income | $682.6M | -$363.3M | -$626.6M | -$559.0M | -$523.9M |
| Balance Sheet | |||||
| Cash and equivalents | $984.6M | $779.7M | $594.0M | $279.8M | $189.7M |
| Current assets | $2.3B | $1.4B | $1.2B | $693.8M | $954.4M |
| Total assets | $2.9B | $1.7B | $1.9B | $1.7B | $1.9B |
| Current liabilities | $968.4M | $581.0M | $603.1M | $406.2M | $509.3M |
| Total liabilities | $3.1B | $2.8B | $2.7B | $2.1B | $1.9B |
| Stockholders' equity | -$205.3M | -$1.1B | -$818.6M | -$347.1M | $1.4M |
| Cash Flow Statement | |||||
| Cash from operations | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M |
| Depreciation and amortization | $38.8M | $75.7M | $236.6M | $128.8M | $64.1M |
| Stock-based compensation | $74.5M | $74.6M | $101.6M | $110.3M | $103.5M |
| Capital expenditure | $8.9M | $6.5M | $28.4M | $32.0M | $28.2M |
| Free cash flow | $702.3M | -$114.2M | -$186.9M | -$388.7M | -$279.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 8.3M · Free float 74.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.